secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2024-07-19T23:59:59+00:00
Accession:  0001615219-24-000058
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Salarius closes Phase 1/2 seclidemstat Ewing sarcoma trial; explores strategic alternatives
--------------------------------------------------------------------------------

- Company terminates ongoing Phase 1/2 clinical trial evaluating seclidemstat for Ewing sarcoma to conserve cash.
- Board of Directors continues exploring strategic alternatives focused on maximizing shareholder value.
- Still supporting MD Anderson's sponsored trial of seclidemstat + azacitidine in MDS/CMML (on partial clinical hold after grade 4 adverse event).
- Warns it may need to dissolve if unable to raise capital or complete a strategic transaction soon.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521924000058/0001615219-24-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521924000058/flks-20240719.htm
  HTML page:      https://secwatch.observer/filing/0001615219-24-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer